Early detection of chronic obstructive pulmonary disease (COPD): The role of spirometry as a diagnostic tool in primary care

Primary Care Respiratory Journal

Volumn 12, Issue 3, 2003, Pages 90-93

  Van Schayck, Onno C P ^a   D'Urzo, Anthony ^b   Invernizzi, Giovanni ^e   Román, Miguel ^c   Ställberg, Björn ^d   Urbina, Christopher ^e  

^a MAASTRICHT UNIVERSITY   (Netherlands)

^b Primary Care Lung Clinic   (Canada)

^c Centro de Salud   (Spain)

^d Vardcentralen   (Sweden)

^e NONE

Author keywords

[No Author keywords available]

Indexed keywords

ASTHMA; CHRONIC OBSTRUCTIVE LUNG DISEASE; DIAGNOSTIC ERROR; DIAGNOSTIC TEST; DIFFERENTIAL DIAGNOSIS; DISEASE COURSE; HIGH RISK PATIENT; HUMAN; INCIDENCE; LUNG FUNCTION TEST; MOTIVATION; PATIENT MONITORING; PRIMARY MEDICAL CARE; REVIEW; SMOKING; SPIROMETRY;

EID: 0242323681     PISSN: 14714418     EISSN: None     Source Type: Journal    
DOI: 10.1038/pcrj.2003.54     Document Type: Review

References (26)

1. Global Initiative for Chronic Obstructive Lung Disease. NHLBI/WHO workshop report on Global Strategy for the Diagnosis, Management, and Prevention of Chronic Obstructive Pulmonary Disease. National Institutes of Health National Heart, Lung, and Blood Institute. March 2001;Updated 2003. NIH Publication No 2701A (http://wwwgoldcopd.com; accessed July 31, 2003).
2. Barnes PJ. Chronic obstructive pulmonary disease. N Engl J Med 2000;343:269-80.
3. Agusti AGN, Noguera A, Sauleda J, Sala E, Pons J, Busquets X. Systemic effects of chronic obstructive pulmonary disease. Eur Respir J 2003;21:347-360.
4. World Health Report 1998. Life in the 21st Century: A vision for all. World Health Organization, Geneva, 1998.
5. Murray CJL, Lopez AD, Mathers CD, Stein C. The global burden of disease 2000 project: aims, methods and data sources. Global Programme on Evidence for Health Policy Discussion Paper No.36. World Health Organization, Nov 2001.
6. Murray CJL, Lopez AD. The global burden of disease: a comprehensive assessment of mortality and disability from diseases, injuries and risk factors in 1990, and projected to 2020. Harvard University Press: Cambridge MA 1996
7. U.S. Department of Commerce, Bureau of the Census. Statistical Abstract of the United States 1997. Washington (DC): Department of Commerce; 1997.
8. National Institutes of Health. National Heart, Lung and Blood Institute. Morbidity and Mortality: 2002 Chart Book on Cardiovascular, Lung and Blood Diseases. July 2003. (http://www.nhlbi.nih.gov; accessed July 31, 2003).
9. Strategies in preserving lung health and preventing COPD and associated diseases. The National Lung Health Education Program (NLHEP). Chest 1998;113:123S-163S.
10. Donaldson GC, Seemungal T, Jeffries DJ, Wedzicha JA. Effect of temperature on lung function and symptoms in chronic obstructive pulmonary disease. Eur Respir J 1999;13:844-9.
11. Seemungal TA, Donaldson GC, Paul EA, Bestall JC, Jeffries DJ, Wedzicha JA. Effect of exacerbation on quality of life in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 1998;157:1418-22.
12. Coultas DB, Mapel D, Gagnon R, Lydick E. The health impact of undiagnosed airflow obstruction in a national sample of United States adults. Am J Respir Crit Care Med 2001;164:372-7.
13. Enright PL, Crapo RO. Controversies in the use of spirometry for early recognition and diagnosis of chronic obstructive pulmonary disease in cigarette smokers. Clin Chest Med 2000;21:645-52.
14. Ferguson GT, Enright PL, Buist S, Higgins MW. Office spirometry for lung health assessment in adults. A consensus statement from the National Lung Health Education Program. Chest 2000;117:1146-61.
15. Law M, Tang JL. An analysis of the effectiveness of interventions intended to help people stop smoking. Arch Intern Med 1995;155:1933-1941.
16. Morris JF, Temple W. Spirometric 'lung age' estimation for motivating smoking cessation. Prev Med 1985;14:655-62.
17. Risser NL, Belcher DW. Adding spirometry, carbon monoxide and pulmonary symptom results to smoking cessation counseling: A randomized trial. J Gen Intern Med 1990;5:16-22.
18. Hepper NG, Drage CW, Davies SF, et al. Chronic obstructive pulmonary disease: A community-oriented program including professional education and screening by a voluntary health agency. Am Rev Respir Dis 1980;121:97-104.
19. Fletcher C, Peto R. The natural history of chronic airflow obstruction. BMJ 1977;1:1645-8.
20. D'Urzo A. Differentiating asthma from COPD in primary care. Ont Thoracic Rev 2001;13:3-7.
21. Eaton T, Withy S, Garrett JE, Mercer J, Whitlock RML, Rea HH. Spirometry in primary care practice. The importance of quality assurance and the impact of spirometry workshops. Chest 1999;116:416-423.
22. Petty TL, Enright PL. Simple office spirometry for primary care practitioners. June 2003 (http://www.nlhep.org/resources.html#phys; accessed July 31, 2003)
23. Paggiaro PL, Dahle R, Bakran I, Frith L, Hollingsworth K, Efthimiou J, on behalf of the International COPD Study Group. Multicentre randomised placebo-controlled trial of inhaled fluticasone propionate in patients with chronic obstructive pulmonary disease. The Lancet 1998;351:773-780.
24. Dompeling E, van Schayk CP, van Grunsven PM, et al. Slowing the deterioration of asthma and chronic obstructive pulmonary disease observed during bronchodilator therapy by adding inhaled corticosteroids. A 4-year prospective study. Ann Intern Med 1993;118:770-8.
25. Calverley PMA, Pauwels R, Vestbo J, et al. Combined salmeterol and fluticasone in the treatment of chronic obstructive pulmonary disease: A randomized controlled trial. The Lancet 2003; 361:449-56.
26. Soriano JB, Vestbo J, Pride NB, Kiri V, Maden C, Maier WC. Survival in COPD patients after regular use of fluticasone propionate and salmeterol in general practice. Eur Respir J 2002;20:819-25.